Nadolol (tablet): Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
Line 1: Line 1:
__NOTOC__
{{DrugProjectFormSinglePage
{{Nadolol}}
|genericName=generic name
|aOrAn=a
|drugClass=Adrenergic receptor agonist
|indication=a list of indications, separated by commas.
|hasBlackBoxWarning=Yes
|adverseReactions=a list of adverse reactions, separated by commas.
|blackBoxWarningTitle=Warning Title
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
|fdaLIADAdult======Condition 1=====


{{CMG}}; {{AE}} {{AZ}}
* Dosing Information


'''''For patient information about Nadolol, click [[Nadolol (patient information)|here]].'''''
:* (Dosage)


{{SB}} CORGARD<sup>®</sup>
=====Condition 2=====


==Overview==
* Dosing Information


'''Nadolol''' ('''Corgard''', '''Anabet''', '''Solgol''', '''Corzide''', '''Alti-Nadolol''', '''Apo-Nadol''', '''Novo-Nadolol''') is a non-selective [[beta blocker]] used in the treatment of [[hypertension|high blood pressure]] and [[angina pectoris|chest pain]] (its only [[FDA]] approved uses).<ref name = "dfac">{{cite book | title = Drug Facts And Comparisons | edition = 2011 | publisher = Wolters Kluwer Health | location = 77 Westport Plaza, Suite 450, St. Louis, Missouri | pages = (4)775}}</ref> Additionally, it is often prescribed in the treatment of [[Migraine|migraine headaches]], [[adult attention deficit hyperactivity disorder]],<ref>http://books.google.com/books?id=EkyTTvjNRZAC&pg=PA669&lpg=PA669&dq=Nadolol+for+ADHD&source=bl&ots=AGG0LAgDus&sig=ctayeAWE3Nkoki-_EhfeLJ2uR1I&hl=en&sa=X&ei=9a40UvX7G8nDqQHSm4HQCg&ved=0CHYQ6AEwCDgK#v=onepage&q=Nadolol%20for%20ADHD&f=true</ref> [[essential tremor]], and [[Parkinson's disease]].<ref>http://books.google.com/books?id=EkyTTvjNRZAC&pg=PA669&lpg=PA669&dq=Nadolol+for+ADHD&source=bl&ots=AGG0LAgDus&sig=ctayeAWE3Nkoki-_EhfeLJ2uR1I&hl=en&sa=X&ei=9a40UvX7G8nDqQHSm4HQCg&ved=0CHYQ6AEwCDgK#v=onepage&q=Nadolol%20for%20ADHD&f=true</ref><ref>http://www.ncbi.nlm.nih.gov/pubmed/6348587</ref><ref>http://www.drugs.com/dosage/nadolol.html#Usual_Adult_Dose_for_Parkinsonian_Tremor</ref>
:* (Dosage)
|offLabelAdultGuideSupport======Condition 1=====


==Category==
* Developed by: (Organisation)


Beta blockers
* Class of Recommendation: (Class) (Link)


==FDA Package Insert==
* Strength of Evidence: (Category A/B/C) (Link)


====CORGARD (nadolol) tablet====
* Dosing Information/Recommendation


'''  [[Nadolol indications and usage|Indications and Usage]]'''
:* (Dosage)
'''| [[Nadolol dosage and administration|Dosage and Administration]]'''
'''| [[Nadolol dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[Nadolol contraindications|Contraindications]]'''
'''| [[Nadolol warnings and precautions|Warnings and Precautions]]'''
'''| [[Nadolol adverse reactions|Adverse Reactions]]'''
'''| [[Nadolol drug interactions|Drug Interactions]]'''
'''| [[Nadolol use in specific populations|Use in Specific Populations]]'''
'''| [[Nadolol overdosage|Overdosage]]'''
'''| [[Nadolol description|Description]]'''
'''| [[Nadolol clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Nadolol nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[Nadolol clinical studies|Clinical Studies]]'''
'''| [[Nadolol how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[Nadolol patient counseling information|Patient Counseling Information]]'''
'''| [[Nadolol labels and packages|Labels and Packages]]'''


==Mechanism of Action==
=====Condition 2=====


Nadolol is a non-selective [[beta blocker]]; that is, it non-selectively blocks both [[beta-1 receptor|beta-1]] and [[beta-2 receptor]]s. It has a preference for beta-1 receptors, which are predominantly located in the [[heart]], thereby inhibiting the effects of [[catecholamine]]s and causing a decrease in [[heart rate]] and [[blood pressure]]. Its inhibition of [[beta-2]] receptors, which are mainly located in the [[bronchus|bronchial]] [[smooth muscle]] of the [[airway]]s, leads to airway constriction similar to that seen in [[asthma]]. Inhibition of beta-1 receptors in the [[juxtaglomerular apparatus]] of the [[kidney]] inhibits the [[renin-angiotensin system]], causing a decrease in [[vasoconstriction]] and a decrease in water retention. Nadolol's inhibition of [[beta-1]] receptors in the heart and kidney leads to its effects on lowering blood pressure.
* Developed by: (Organisation)


The drug impairs [[atrioventricular node|AV node]] conduction and decreases [[sinoatrial node|sinus]] rate.
* Class of Recommendation: (Class) (Link)


Nadolol may also increase [[blood plasma|plasma]] [[triglyceride]]s and decrease [[High density lipoprotein|HDL]]-[[cholesterol]] levels.
* Strength of Evidence: (Category A/B/C) (Link)


==Indications==
* Dosing Information/Recommendation


Nadolol has U.S. [[Food and Drug Administration]] approved indications for:
:* (Dosage)
* treatment of [[hypertension]]
|offLabelAdultNoGuideSupport======Condition 1=====
* long-term treatment of [[angina pectoris]].<ref name = "dfac"/>


==Off-label uses==
* Dosing Information


* '''Neurological disorders'''
:* (Dosage)


:Nadolol is used in the treatment of a number of [[neurological disorder]]s such as [[migraine]], [[adult ADHD]], [[essential tremor]], [[Parkinson's disease]]. Prevention of migraine headaches with nadolol is well documented.<ref name = "dfac"/>
=====Condition 2=====


:A case report study from Harvard Medical School, published in 1991, described three adult patients with [[ADHD]] for whom traditional [[psychostimulant]] therapy (with [[methylphenidate]]) was either ineffective or wasn't well tolerated. Adding nadolol to the psychostimulant monotherapy resulted in improved attention and focus with decreased side effects. This suggested that [[combination therapy]] with nadolol and a psychostimulant (such as methylphenidate or [[dexamphetamine]]) might be effective for treatment-resistant ADHD in adults.<ref>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1940895&dopt=Abstract</ref><ref>http://books.google.com/books?id=EkyTTvjNRZAC&pg=PA669&lpg=PA669&dq=Nadolol+for+ADHD&source=bl&ots=AGG0LAgDus&sig=ctayeAWE3Nkoki-_EhfeLJ2uR1I&hl=en&sa=X&ei=9a40UvX7G8nDqQHSm4HQCg&ved=0CHYQ6AEwCDgK#v=onepage&q=Nadolol%20for%20ADHD&f=true</ref>
* Dosing Information


:Nadolol is also used to control tremors in [[degenerative disease]]s of the [[central nervous system]] (such as [[essential tremor]]) or as an anti-tremor agent in the treatment of [[Parkinson's disease]].<ref>http://www.drugs.com/dosage/nadolol.html#Usual_Adult_Dose_for_Parkinsonian_Tremor</ref>
:* (Dosage)


* '''Long QT syndrome (LQTS)'''
=====Condition 3=====


:Nadolol is one of the preferred [[beta-blockers]] in the management of patients with [[long QT syndrome | LQTS]] for shortening of the QT interval and prevention of [[ventricular arrhythmia]]. It is more efficacious than [[metoprolol]] in the prevention of breakthrough cardiac events while on therapy and is equivalent to [[propranolol]].<ref>{{cite journal|last=Chockalingam|first=P|coauthors=Crotti, L; Girardengo, G; Johnson, JN; Harris, KM; van der Heijden, JF; Hauer, RN; Beckmann, BM; Spazzolini, C; Rordorf, R; Rydberg, A; Clur, SA; Fischer, M; van den Heuvel, F; Kääb, S; Blom, NA; Ackerman, MJ; Schwartz, PJ; Wilde, AA|title=Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol|journal=Journal of the American College of Cardiology|date=Nov 13, 2012|volume=60|issue=20|pages=2092–9|pmid=23083782}}</ref> Nadolol has the advantage of once daily dosing and thus improved patient compliance.
* Dosing Information


==Contraindications==
:* (Dosage)
|fdaLIADPed======Condition 1=====


Patients whose heart rate is largely mediated by the [[sympathetic nervous system]] (e.g. patients with [[congestive heart failure]] or [[myocardial infarction|myocardial infarct]]) should avoid nadolol as it inhibits sympathetic function. Nadolol is also contraindicated in patients with [[bradycardia]] (slow heart rate) because of its vasodilatory effects and tendency to cause bradycardia.
* Dosing Information


Because of its beta-2 activity, nadolol causes pulmonary bronchoconstriction and should be avoided in [[asthma]] patients in preference of a [[beta blocker|beta-1 blocker]]. However, evidence from a 2008 study suggests that long-term non-selective beta-blocker use may actually prove to be beneficial in mild asthma.<ref>http://ajrcmb.atsjournals.org/content/38/3/249.full</ref>
:* (Dosage)


Because nadolol, like other beta-2 blockers, inhibits the synthesis and release of [[glucose]] in response to [[hypoglycemia]], it slows patients' recovery from acute hypoglycemic episodes and should be avoided in patients getting treatment for [[diabetes mellitus]]. In patients with [[insulin]]-dependent diabetes, a selective beta-1 blocker is preferred over non-selective blockers.
=====Condition 2=====


==Side effects==
* Dosing Information


* [[Bradycardia]]
:* (Dosage)
* [[Fatigue (physical)|Fatigue]]
|offLabelPedGuideSupport======Condition 1=====
* [[Bronchospasm]]s


==Chemistry==
* Developed by: (Organisation)


Nadolol is a mixture of [[stereoisomer]]s. It is [[Chemical polarity | polar]] and [[Hydrophile | hydrophilic]], with low [[lipid]] solubility.
* Class of Recommendation: (Class) (Link)


==References==
* Strength of Evidence: (Category A/B/C) (Link)


{{Reflist|2}}
* Dosing Information/Recommendation


[[Category:Drugs]]
:* (Dosage)
 
=====Condition 2=====
 
* Developed by: (Organisation)
 
* Class of Recommendation: (Class) (Link)
 
* Strength of Evidence: (Category A/B/C) (Link)
 
* Dosing Information/Recommendation
 
:* (Dosage)
|offLabelPedNoGuideSupport======Condition 1=====
 
* Dosing Information
 
:* (Dosage)
 
=====Condition 2=====
 
* Dosing Information
 
:* (Dosage)
 
=====Condition 3=====
 
* Dosing Information
 
:* (Dosage)
|contraindications=* Condition 1
* Condition 2
* Condition 3
* Condition 4
* Condition 5
|warnings======Conidition 1=====
 
(Description)
 
|clinicalTrials=======Central Nervous System======
 
: (list/description of adverse reactions)
 
======Cardiovascular======
 
: (list/description of adverse reactions)
 
======Respiratory======
 
: (list/description of adverse reactions)
 
======Gastrointestinal======
 
: (list/description of adverse reactions)
 
======Hypersensitive Reactions======
 
: (list/description of adverse reactions)
 
======Miscellaneous======
 
: (list/description of adverse reactions)
 
=====Condition 2=====
 
======Central Nervous System======
 
: (list/description of adverse reactions)
 
======Cardiovascular======
 
: (list/description of adverse reactions)
 
======Respiratory======
 
: (list/description of adverse reactions)
 
======Gastrointestinal======
 
: (list/description of adverse reactions)
 
======Hypersensitive Reactions======
 
: (list/description of adverse reactions)
 
======Miscellaneous======
 
: (list/description of adverse reactions)
|postmarketing=(Description)
|drugInteractions=* Drug 1
* Drug 2
* Drug 3
* Drug 4
* Drug 5
 
=====Drug 1=====
 
(Description)
 
=====Drug 2=====
 
(Description)
 
=====Drug 3=====
 
(Description)
 
=====Drug 4=====
 
(Description)
 
=====Drug 5=====
 
(Description)
|useInPregnancyFDA=(Description)
|useInPregnancyAUS=(Description)
|useInLaborDelivery=(Description)
|useInNursing=(Description)
|useInPed=(Description)
|useInGeri=(Description)
|useInGender=(Description)
|useInRace=(Description)
|useInRenalImpair=(Description)
|useInHepaticImpair=(Description)
|useInReproPotential=(Description)
|useInImmunocomp=(Description)
|othersTitle=Others
|useInOthers=(Description)
 
|administration=(Oral/Intravenous/etc)
|monitoring======Condition 1=====
 
(Description regarding monitoring, from ''Warnings'' section)
 
=====Condition 2=====
 
(Description regarding monitoring, from ''Warnings'' section)
 
=====Condition 3=====
 
(Description regarding monitoring, from ''Warnings'' section)
|IVCompat====Solution===
 
====Compatible====
 
* Solution 1
* Solution 2
* Solution 3
 
====Not Tested====
 
* Solution 1
* Solution 2
* Solution 3
 
====Variable====
 
* Solution 1
* Solution 2
* Solution 3
 
====Incompatible====
 
* Solution 1
* Solution 2
* Solution 3
 
===Y-Site===
 
====Compatible====
 
* Solution 1
* Solution 2
* Solution 3
 
====Not Tested====
 
* Solution 1
* Solution 2
* Solution 3
 
====Variable====
 
* Solution 1
* Solution 2
* Solution 3
 
====Incompatible====
 
* Solution 1
* Solution 2
* Solution 3
 
===Admixture===
 
====Compatible====
 
* Solution 1
* Solution 2
* Solution 3
 
====Not Tested====
 
* Solution 1
* Solution 2
* Solution 3
 
====Variable====
 
* Solution 1
* Solution 2
* Solution 3
 
====Incompatible====
 
* Solution 1
* Solution 2
* Solution 3
 
===Syringe===
 
====Compatible====
 
* Solution 1
* Solution 2
* Solution 3
 
====Not Tested====
 
* Solution 1
* Solution 2
* Solution 3
 
====Variable====
 
* Solution 1
* Solution 2
* Solution 3
 
====Incompatible====
 
* Solution 1
* Solution 2
* Solution 3
 
===TPN/TNA===
 
====Compatible====
 
* Solution 1
* Solution 2
* Solution 3
 
====Not Tested====
 
* Solution 1
* Solution 2
* Solution 3
 
====Variable====
 
* Solution 1
* Solution 2
* Solution 3
 
====Incompatible====
 
* Solution 1
* Solution 2
* Solution 3
|overdose====Acute Overdose===
 
====Signs and Symptoms====
 
(Description)
 
====Management====
 
(Description)
 
===Chronic Overdose===
 
====Signs and Symptoms====
 
(Description)
 
====Management====
 
(Description)
|drugBox={{Drugbox2
| verifiedrevid =
| IUPAC_name =
| image =
| drug_name =
 
<!--Clinical data-->
| tradename =
| MedlinePlus =
| licence_US =
| pregnancy_AU =
| pregnancy_US =
| legal_status =
| routes_of_administration =
 
<!--Pharmacokinetic data-->
| bioavailability =
| metabolism =
| elimination_half-life =
| excretion =
 
<!--Identifiers-->
| CAS_number_Ref =
| CAS_number =
| ATC_prefix =
| ATC_suffix =
| PubChem =
| IUPHAR_ligand =
| DrugBank_Ref =
| DrugBank =
| ChemSpiderID_Ref =
| ChemSpiderID =
| UNII_Ref =
| UNII =
| KEGG_Ref =
| KEGG =
| ChEBI_Ref =
| ChEBI =
| ChEMBL_Ref =
| ChEMBL =
 
<!--Chemical data-->
| C= | H= | N= | O=
| molecular_weight =
| smiles =
| InChI =
| InChIKey =
| StdInChI_Ref =
| StdInChI =
| StdInChIKey_Ref =
| StdInChIKey =
| melting_point =
}}
|mechAction=(Description)
|structure=(Description with picture)
|PD=(Description)
|PK=(Description)
|nonClinToxic=(Description)
|clinicalStudies======Condition 1=====
 
(Description)
 
=====Condition 2=====
 
(Description)
 
=====Condition 3=====
 
(Description)
|howSupplied=(Description)
|fdaPatientInfo=(Patient Counseling Information)
|nlmPatientInfo=(Link to patient information page)
|lookAlike=* (Paired Confused Name 1a) — (Paired Confused Name 1b)
* (Paired Confused Name 2a) — (Paired Confused Name 2b)
* (Paired Confused Name 3a) — (Paired Confused Name 3b)
|drugShortage=Drug Shortage
}}

Revision as of 17:47, 7 July 2014

Nadolol (tablet)
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

Warning Title
See full prescribing information for complete Boxed Warning.
Condition Name: (Content)

Overview

Nadolol (tablet) is a Adrenergic receptor agonist that is FDA approved for the {{{indicationType}}} of a list of indications, separated by commas.. There is a Black Box Warning for this drug as shown here. Common adverse reactions include a list of adverse reactions, separated by commas..

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Condition 1
  • Dosing Information
  • (Dosage)
Condition 2
  • Dosing Information
  • (Dosage)

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition 1
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)
Condition 2
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)

Non–Guideline-Supported Use

Condition 1
  • Dosing Information
  • (Dosage)
Condition 2
  • Dosing Information
  • (Dosage)
Condition 3
  • Dosing Information
  • (Dosage)

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition 1
  • Dosing Information
  • (Dosage)
Condition 2
  • Dosing Information
  • (Dosage)

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition 1
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)
Condition 2
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)

Non–Guideline-Supported Use

Condition 1
  • Dosing Information
  • (Dosage)
Condition 2
  • Dosing Information
  • (Dosage)
Condition 3
  • Dosing Information
  • (Dosage)

Contraindications

  • Condition 1
  • Condition 2
  • Condition 3
  • Condition 4
  • Condition 5

Warnings

Warning Title
See full prescribing information for complete Boxed Warning.
Condition Name: (Content)
Conidition 1

(Description)

Adverse Reactions

Clinical Trials Experience

Central Nervous System
(list/description of adverse reactions)
Cardiovascular
(list/description of adverse reactions)
Respiratory
(list/description of adverse reactions)
Gastrointestinal
(list/description of adverse reactions)
Hypersensitive Reactions
(list/description of adverse reactions)
Miscellaneous
(list/description of adverse reactions)
Condition 2
Central Nervous System
(list/description of adverse reactions)
Cardiovascular
(list/description of adverse reactions)
Respiratory
(list/description of adverse reactions)
Gastrointestinal
(list/description of adverse reactions)
Hypersensitive Reactions
(list/description of adverse reactions)
Miscellaneous
(list/description of adverse reactions)

Postmarketing Experience

(Description)

Drug Interactions

  • Drug 1
  • Drug 2
  • Drug 3
  • Drug 4
  • Drug 5
Drug 1

(Description)

Drug 2

(Description)

Drug 3

(Description)

Drug 4

(Description)

Drug 5

(Description)

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): (Description)
Pregnancy Category (AUS): (Description)

Labor and Delivery

(Description)

Nursing Mothers

(Description)

Pediatric Use

(Description)

Geriatic Use

(Description)

Gender

(Description)

Race

(Description)

Renal Impairment

(Description)

Hepatic Impairment

(Description)

Females of Reproductive Potential and Males

(Description)

Immunocompromised Patients

(Description)

Others

(Description)

Administration and Monitoring

Administration

(Oral/Intravenous/etc)

Monitoring

Condition 1

(Description regarding monitoring, from Warnings section)

Condition 2

(Description regarding monitoring, from Warnings section)

Condition 3

(Description regarding monitoring, from Warnings section)

IV Compatibility

Solution

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

Y-Site

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

Admixture

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

Syringe

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

TPN/TNA

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

Overdosage

Acute Overdose

Signs and Symptoms

(Description)

Management

(Description)

Chronic Overdose

Signs and Symptoms

(Description)

Management

(Description)

Pharmacology

Nadolol (tablet)
Systematic (IUPAC) name
?
Identifiers
CAS number ?
ATC code ?
PubChem ?
Chemical data
Formula ?
Mol. mass ?
Pharmacokinetic data
Bioavailability ?
Metabolism ?
Half life ?
Excretion ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes ?

Mechanism of Action

(Description)

Structure

(Description with picture)

Pharmacodynamics

(Description)

Pharmacokinetics

(Description)

Nonclinical Toxicology

(Description)

Clinical Studies

Condition 1

(Description)

Condition 2

(Description)

Condition 3

(Description)

How Supplied

(Description)

Storage

There is limited information regarding Nadolol (tablet) Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Nadolol (tablet) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Nadolol (tablet) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

(Patient Counseling Information)

Precautions with Alcohol

Alcohol-Nadolol (tablet) interaction has not been established. Talk to your doctor regarding the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Nadolol (tablet) Brand Names in the drug label.

Look-Alike Drug Names

  • (Paired Confused Name 1a) — (Paired Confused Name 1b)
  • (Paired Confused Name 2a) — (Paired Confused Name 2b)
  • (Paired Confused Name 3a) — (Paired Confused Name 3b)

Drug Shortage Status

Drug Shortage

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

Retrieved from "https://www.wikidoc.org/index.php?title=Nadolol_(tablet)&oldid=989806"